This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Discoidin domain receptor tyrosine kinase 2 (DDR2)	<p><i>In vitro</i> and mouse studies suggest inhibiting DDR2 could help treat metastatic breast cancer. In primary invasive breast tumors, DDR2 expression was greater than that in normal breast tissue and correlated with reduced survival. In a human breast cancer cell line, small hairpin RNA against <i>DDR2</i> decreased invasion and migration compared with a scrambled control shRNA. In normal mice, implantation of a mouse breast cancer cell line pretreated with shRNA against <i>Ddr2</i> decreased the number and size of lung metastases compared with implantation of cells pretreated with a scrambled control shRNA. Ongoing work includes a computational screen that identifies small molecule DDR2 inhibitors.</p> <p>SciBX 6(19); doi:10.1038/scibx.2013.461 Published online May 16, 2013</p>	Unpatented; available for licensing or partnering	<p>Zhang, K. <i>et al. Nat. Cell Biol.</i>; published online May 5, 2013; doi:10.1038/ncb2743 Contact: Gregory D. Longmore, Washington University in St. Louis, St. Louis, Mo. e-mail: glongmor@dom.wustl.edu</p>